Stem Cell Therapy for Heart Failure: Ensuring Regenerative Proficiency
Patient-derived stem cells enable promising regenerative strategies but display heterogenous cardiac reparative proficiency, leading to unpredictable therapeutic outcomes impeding practice adoption. Means to establish and certify the regenerative potency of emerging biotherapies are thus warranted....
Gespeichert in:
| Veröffentlicht in: | Trends in cardiovascular medicine 2016-07, Vol.26 (5), p.395-404 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 404 |
|---|---|
| container_issue | 5 |
| container_start_page | 395 |
| container_title | Trends in cardiovascular medicine |
| container_volume | 26 |
| creator | Terzic, Andre, MD, PhD Behfar, Atta, MD, PhD |
| description | Patient-derived stem cells enable promising regenerative strategies but display heterogenous cardiac reparative proficiency, leading to unpredictable therapeutic outcomes impeding practice adoption. Means to establish and certify the regenerative potency of emerging biotherapies are thus warranted. In this era of clinomics, deconvolution of variant cytoreparative performance in clinical trials offers an unprecedented opportunity to map pathways that segregate regenerative from non-regenerative states informing the evolution of cardioregenerative quality systems. A maiden example of this approach is cardiopoiesis-mediated lineage-specification developed to ensure regenerative performance. Successfully tested in pre-clinical and early clinical studies, the safety and efficacy of the cardiopoietic stem cell phenotype is undergoing validation in pivotal trials for chronic ischemic cardiomyopathy offering the prospect of a next-generation regenerative solution for heart failure. |
| doi_str_mv | 10.1016/j.tcm.2016.01.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4912443</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1050173816000219</els_id><sourcerecordid>1797866004</sourcerecordid><originalsourceid>FETCH-LOGICAL-c633t-b3bccd32bba8f5c7efc03e12751b651fc6d5ebf4e522e98f30c2f2ad5a69b5523</originalsourceid><addsrcrecordid>eNqFkk1v1DAQhi0Eoh_wA7igSFy4JIzt2E5AqoRW3RapEoiWs-U4462XfCx2stL-e7zdUqAHOHkkP_Nq3nmHkFcUCgpUvlsXk-0LlsoCaAHAn5BjWimeM0nF01SDgJwqXh2RkxjXACBLSZ-TI6aAQQ3lMVleT9hnC-y67OYWg9nsMjeG7BJNmLKl8d0c8H12PsQ5-GGVfcUVDgmb_BazL2F03noc7O4FeeZMF_Hl_XtKvi3PbxaX-dXni0-Lj1e5lZxPecMba1vOmsZUTliFzgJHypSgjRTUWdkKbFyJgjGsK8fBMsdMK4ysGyEYPyVnB93N3PTYWhymYDq9Cb43YadH4_XfP4O_1atxq8uasrLkSeDtvUAYf8wYJ937aJN9M-A4R00rqFQaiKn_o6pWlZQAZULfPELX4xyGtIk7SrG0d0gUPVA2jDEGdA9zU9D7QPVap0D1PlANVKdAU8_rPw0_dPxKMAEfDgCmtW89Bh3vIsHWB7STbkf_T_mzR92284O3pvuOO4y_XejINOjr_UXtD4om28BozX8CxinFmQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1797726460</pqid></control><display><type>article</type><title>Stem Cell Therapy for Heart Failure: Ensuring Regenerative Proficiency</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Terzic, Andre, MD, PhD ; Behfar, Atta, MD, PhD</creator><creatorcontrib>Terzic, Andre, MD, PhD ; Behfar, Atta, MD, PhD</creatorcontrib><description>Patient-derived stem cells enable promising regenerative strategies but display heterogenous cardiac reparative proficiency, leading to unpredictable therapeutic outcomes impeding practice adoption. Means to establish and certify the regenerative potency of emerging biotherapies are thus warranted. In this era of clinomics, deconvolution of variant cytoreparative performance in clinical trials offers an unprecedented opportunity to map pathways that segregate regenerative from non-regenerative states informing the evolution of cardioregenerative quality systems. A maiden example of this approach is cardiopoiesis-mediated lineage-specification developed to ensure regenerative performance. Successfully tested in pre-clinical and early clinical studies, the safety and efficacy of the cardiopoietic stem cell phenotype is undergoing validation in pivotal trials for chronic ischemic cardiomyopathy offering the prospect of a next-generation regenerative solution for heart failure.</description><identifier>ISSN: 1050-1738</identifier><identifier>EISSN: 1873-2615</identifier><identifier>DOI: 10.1016/j.tcm.2016.01.003</identifier><identifier>PMID: 27020904</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aging ; Algorithms ; Animals ; Cardiopoiesis ; Cardiopoietic stem cell ; Cardiovascular ; Cardiovascular disease ; Cell Differentiation ; Cell Lineage ; Cell Proliferation ; Clinical trial ; Clinical trials ; Clinomics ; Diffusion of Innovation ; Disease management ; Drug therapy ; Epidemic ; Health care ; Heart attacks ; Heart failure ; Heart Failure - pathology ; Heart Failure - physiopathology ; Heart Failure - surgery ; Homeostasis ; Hospitals ; Humans ; Mortality ; Myocardial infarction ; Myocardium - pathology ; Myocytes, Cardiac - pathology ; Myocytes, Cardiac - transplantation ; Next generation ; Phenotype ; Product development ; Quality ; Recovery of Function ; Regeneration ; Regenerative medicine ; Stem Cell Transplantation - adverse effects ; Stem cells ; System ; Translational Medical Research ; Transplants & implants ; Treatment Outcome</subject><ispartof>Trends in cardiovascular medicine, 2016-07, Vol.26 (5), p.395-404</ispartof><rights>2016 The Authors</rights><rights>Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c633t-b3bccd32bba8f5c7efc03e12751b651fc6d5ebf4e522e98f30c2f2ad5a69b5523</citedby><cites>FETCH-LOGICAL-c633t-b3bccd32bba8f5c7efc03e12751b651fc6d5ebf4e522e98f30c2f2ad5a69b5523</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.tcm.2016.01.003$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27020904$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Terzic, Andre, MD, PhD</creatorcontrib><creatorcontrib>Behfar, Atta, MD, PhD</creatorcontrib><title>Stem Cell Therapy for Heart Failure: Ensuring Regenerative Proficiency</title><title>Trends in cardiovascular medicine</title><addtitle>Trends Cardiovasc Med</addtitle><description>Patient-derived stem cells enable promising regenerative strategies but display heterogenous cardiac reparative proficiency, leading to unpredictable therapeutic outcomes impeding practice adoption. Means to establish and certify the regenerative potency of emerging biotherapies are thus warranted. In this era of clinomics, deconvolution of variant cytoreparative performance in clinical trials offers an unprecedented opportunity to map pathways that segregate regenerative from non-regenerative states informing the evolution of cardioregenerative quality systems. A maiden example of this approach is cardiopoiesis-mediated lineage-specification developed to ensure regenerative performance. Successfully tested in pre-clinical and early clinical studies, the safety and efficacy of the cardiopoietic stem cell phenotype is undergoing validation in pivotal trials for chronic ischemic cardiomyopathy offering the prospect of a next-generation regenerative solution for heart failure.</description><subject>Aging</subject><subject>Algorithms</subject><subject>Animals</subject><subject>Cardiopoiesis</subject><subject>Cardiopoietic stem cell</subject><subject>Cardiovascular</subject><subject>Cardiovascular disease</subject><subject>Cell Differentiation</subject><subject>Cell Lineage</subject><subject>Cell Proliferation</subject><subject>Clinical trial</subject><subject>Clinical trials</subject><subject>Clinomics</subject><subject>Diffusion of Innovation</subject><subject>Disease management</subject><subject>Drug therapy</subject><subject>Epidemic</subject><subject>Health care</subject><subject>Heart attacks</subject><subject>Heart failure</subject><subject>Heart Failure - pathology</subject><subject>Heart Failure - physiopathology</subject><subject>Heart Failure - surgery</subject><subject>Homeostasis</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Mortality</subject><subject>Myocardial infarction</subject><subject>Myocardium - pathology</subject><subject>Myocytes, Cardiac - pathology</subject><subject>Myocytes, Cardiac - transplantation</subject><subject>Next generation</subject><subject>Phenotype</subject><subject>Product development</subject><subject>Quality</subject><subject>Recovery of Function</subject><subject>Regeneration</subject><subject>Regenerative medicine</subject><subject>Stem Cell Transplantation - adverse effects</subject><subject>Stem cells</subject><subject>System</subject><subject>Translational Medical Research</subject><subject>Transplants & implants</subject><subject>Treatment Outcome</subject><issn>1050-1738</issn><issn>1873-2615</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkk1v1DAQhi0Eoh_wA7igSFy4JIzt2E5AqoRW3RapEoiWs-U4462XfCx2stL-e7zdUqAHOHkkP_Nq3nmHkFcUCgpUvlsXk-0LlsoCaAHAn5BjWimeM0nF01SDgJwqXh2RkxjXACBLSZ-TI6aAQQ3lMVleT9hnC-y67OYWg9nsMjeG7BJNmLKl8d0c8H12PsQ5-GGVfcUVDgmb_BazL2F03noc7O4FeeZMF_Hl_XtKvi3PbxaX-dXni0-Lj1e5lZxPecMba1vOmsZUTliFzgJHypSgjRTUWdkKbFyJgjGsK8fBMsdMK4ysGyEYPyVnB93N3PTYWhymYDq9Cb43YadH4_XfP4O_1atxq8uasrLkSeDtvUAYf8wYJ937aJN9M-A4R00rqFQaiKn_o6pWlZQAZULfPELX4xyGtIk7SrG0d0gUPVA2jDEGdA9zU9D7QPVap0D1PlANVKdAU8_rPw0_dPxKMAEfDgCmtW89Bh3vIsHWB7STbkf_T_mzR92284O3pvuOO4y_XejINOjr_UXtD4om28BozX8CxinFmQ</recordid><startdate>20160701</startdate><enddate>20160701</enddate><creator>Terzic, Andre, MD, PhD</creator><creator>Behfar, Atta, MD, PhD</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160701</creationdate><title>Stem Cell Therapy for Heart Failure: Ensuring Regenerative Proficiency</title><author>Terzic, Andre, MD, PhD ; Behfar, Atta, MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c633t-b3bccd32bba8f5c7efc03e12751b651fc6d5ebf4e522e98f30c2f2ad5a69b5523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Aging</topic><topic>Algorithms</topic><topic>Animals</topic><topic>Cardiopoiesis</topic><topic>Cardiopoietic stem cell</topic><topic>Cardiovascular</topic><topic>Cardiovascular disease</topic><topic>Cell Differentiation</topic><topic>Cell Lineage</topic><topic>Cell Proliferation</topic><topic>Clinical trial</topic><topic>Clinical trials</topic><topic>Clinomics</topic><topic>Diffusion of Innovation</topic><topic>Disease management</topic><topic>Drug therapy</topic><topic>Epidemic</topic><topic>Health care</topic><topic>Heart attacks</topic><topic>Heart failure</topic><topic>Heart Failure - pathology</topic><topic>Heart Failure - physiopathology</topic><topic>Heart Failure - surgery</topic><topic>Homeostasis</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Mortality</topic><topic>Myocardial infarction</topic><topic>Myocardium - pathology</topic><topic>Myocytes, Cardiac - pathology</topic><topic>Myocytes, Cardiac - transplantation</topic><topic>Next generation</topic><topic>Phenotype</topic><topic>Product development</topic><topic>Quality</topic><topic>Recovery of Function</topic><topic>Regeneration</topic><topic>Regenerative medicine</topic><topic>Stem Cell Transplantation - adverse effects</topic><topic>Stem cells</topic><topic>System</topic><topic>Translational Medical Research</topic><topic>Transplants & implants</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Terzic, Andre, MD, PhD</creatorcontrib><creatorcontrib>Behfar, Atta, MD, PhD</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Trends in cardiovascular medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Terzic, Andre, MD, PhD</au><au>Behfar, Atta, MD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stem Cell Therapy for Heart Failure: Ensuring Regenerative Proficiency</atitle><jtitle>Trends in cardiovascular medicine</jtitle><addtitle>Trends Cardiovasc Med</addtitle><date>2016-07-01</date><risdate>2016</risdate><volume>26</volume><issue>5</issue><spage>395</spage><epage>404</epage><pages>395-404</pages><issn>1050-1738</issn><eissn>1873-2615</eissn><abstract>Patient-derived stem cells enable promising regenerative strategies but display heterogenous cardiac reparative proficiency, leading to unpredictable therapeutic outcomes impeding practice adoption. Means to establish and certify the regenerative potency of emerging biotherapies are thus warranted. In this era of clinomics, deconvolution of variant cytoreparative performance in clinical trials offers an unprecedented opportunity to map pathways that segregate regenerative from non-regenerative states informing the evolution of cardioregenerative quality systems. A maiden example of this approach is cardiopoiesis-mediated lineage-specification developed to ensure regenerative performance. Successfully tested in pre-clinical and early clinical studies, the safety and efficacy of the cardiopoietic stem cell phenotype is undergoing validation in pivotal trials for chronic ischemic cardiomyopathy offering the prospect of a next-generation regenerative solution for heart failure.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>27020904</pmid><doi>10.1016/j.tcm.2016.01.003</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1050-1738 |
| ispartof | Trends in cardiovascular medicine, 2016-07, Vol.26 (5), p.395-404 |
| issn | 1050-1738 1873-2615 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4912443 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Aging Algorithms Animals Cardiopoiesis Cardiopoietic stem cell Cardiovascular Cardiovascular disease Cell Differentiation Cell Lineage Cell Proliferation Clinical trial Clinical trials Clinomics Diffusion of Innovation Disease management Drug therapy Epidemic Health care Heart attacks Heart failure Heart Failure - pathology Heart Failure - physiopathology Heart Failure - surgery Homeostasis Hospitals Humans Mortality Myocardial infarction Myocardium - pathology Myocytes, Cardiac - pathology Myocytes, Cardiac - transplantation Next generation Phenotype Product development Quality Recovery of Function Regeneration Regenerative medicine Stem Cell Transplantation - adverse effects Stem cells System Translational Medical Research Transplants & implants Treatment Outcome |
| title | Stem Cell Therapy for Heart Failure: Ensuring Regenerative Proficiency |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T18%3A15%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stem%20Cell%20Therapy%20for%20Heart%20Failure:%20Ensuring%20Regenerative%20Proficiency&rft.jtitle=Trends%20in%20cardiovascular%20medicine&rft.au=Terzic,%20Andre,%20MD,%20PhD&rft.date=2016-07-01&rft.volume=26&rft.issue=5&rft.spage=395&rft.epage=404&rft.pages=395-404&rft.issn=1050-1738&rft.eissn=1873-2615&rft_id=info:doi/10.1016/j.tcm.2016.01.003&rft_dat=%3Cproquest_pubme%3E1797866004%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1797726460&rft_id=info:pmid/27020904&rft_els_id=S1050173816000219&rfr_iscdi=true |